Characterizing the gut microbial ecosystem for diagnosis and therapy in IBD

炎症性肠病（IBD）包括克罗恩病（CD）和溃疡性结肠炎（UC），影响约150万美国人。 约25%的病例发生在儿童中，在过去50年中，总体发病率增加了>400%。CD和UC都是复杂疾病 这种疾病在不同的患者中表现和发展的方式不同，最近的研究发现，他们的遗传风险也同样复杂。研究 环境与IBD的关联尚未导致简单的诊断标志物或可治疗的干预点。相反，IBD 已经成为与肠道微生物群相关的最重要的人类疾病之一，肠道微生物群是细菌，病毒，古细菌， 和真菌有机体通常居住在肠道。IBD与肠道微生物的关联再次复杂，没有单一的微生物或微生物。 病原体似乎是因果关系。相反，IBD与整个肠道微生物生态系统的整体生态反复相关。这 表明，这种疾病可能是最好的研究，通过整合许多不同类型的肠道微生物的测量，因为他们改变内 IBD患者和非IBD对照随时间的变化。因此，该项目将在IBD多组学数据库IBDMDB中提供此类数据， 整合资源，使肠道微生物生态系统成为IBD诊断、治疗和机制理解的目标。它将 利用现有的，良好的表型队列，提供纵向分类，宏基因组学，元转录组学，元蛋白质组学， 肠道微生物组的代谢组学分析。为了进一步提供宿主相互作用机制的数据，我们将分析宿主遗传学， 表观遗传学和转录活性。这些数据将在一年内从90名受试者中产生，它们将迅速产生， 通过建立在我们当前的Meta组学计算基础设施上，可以向社区提供。样本采集和 生物信息学协议将得到验证和分发，该研究将为单细胞和以宿主为重点的 Meta组学测定。我们的团队包括人类微生物组，IBD，微生物群落生态学和功能研究的领导者， Meta数据集成我们组织了一个多元化的合作者团队，包括人类微生物组项目的关键参与者。我们 组织包括项目管理组件;样品生成和数据生成;包括五种不同的测定 多组学平台和技术开发;以及计算基础设施。我们致力于将所有生成的数据发布到 在必要时使用受控访问数据库及时向公众披露，同时维护受试者隐私。我们已经组建 构建一个确定的多组学数据资源所需的专业知识和资源，以了解肠道微生物组在IBD中的作用。

Inflammatory bow/el diseases (IBD) comprise both Crohn's disease (CD) and-ulcerative colitis (UC) and affect some 1.5 million Americans. -25% of cases occur in children, and overall incidence has increased >400% in the past 50 years. CD and UC are both complex diseases that can manifest and proceed differently among patients, and recent studies have found that their genetic risk is likewise complex. Studies of environmental associations with IBD have not yet resulted in simple diagnostic markers or treatable points of intervention. Instead, IBD has emerged in as one of the most important human conditions linked to the gut microbiota, the complex mixture of bacterial, viral, archaeal, and fungal organisms normally resident in the gut. The association of IBD with gut microbes is again complex, with no single microbe or pathogen appearing to be causal. Instead, IBD has been repeatedly linked to the overall ecology of entire gut microbial ecosystem. This suggests that the disease may be best studied by integrating many different types of measurements of gut microbes as they change within IBD patients and non-IBD controls over time. This project will thus provide such data in an IBD multi'omic database, the IBDMDB, an integrated resource enabling the gut microbial ecosystem as a target for diagnosis, therapy, and mechanistic understanding of IBD. It will leverage existing, well-phenotyped cohorts to provide longitudinal taxonomic, metagenomic, metatranscriptomic, metaproteomic, and metabolomic profiling of the gut microbiome. To further provide data on host interaction mechanisms, we will profile host genetics, epigenetics, and transcriptional activity. These data will be generated from 90 subjects over one year, and they will be made rapidly and accessibly available to the community by building on our current meta'omic computational infrastructure. Both sample collection and bioinformatic protocols will be validated and distributed, and the study will result in forward-looking platforms for single-cell and host-focused meta'omic assays. Our team includes leaders in the study of the human microbiome, IBD, microbial community ecology and function, and meta'omic data integration. We have organized a diverse group of collaborators, including key players in the Human Microbiome Project. Our organization includes Components for Project Management; Sample Generation and Data Generation; assays including five different multi'omics platforms and Technology Development; and Computational Infrastructure. We are committed to releasing all generated data to the public in a timely manner while maintaining subject privacy using controlled access databases whenever necessary. We have assembled the expertise and resources necessary to construct a definitive multi'omic data resource to understand the gut microbiome's role in IBD.